Mylan Scores Costs After Win In Blood-Thinner IP Row
Mylan on Monday scored nearly all of the litigation costs it requested in a six-year dispute with The Medicines Co. over a generic version for the blood-thinner Angiomax, with an Illinois...To view the full article, register now.
Already a subscriber? Click here to view full article